GlassScriptPhysician profile
Mark Thomas Toyama
NPI 1821085358
$6,579.74
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,253 · 2020: $384 · 2021: $873 · 2022: $626 · 2023: $420 · 2024: $23.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,017.10 | 2019-2021 | |
| Novo Nordisk INC | $259.47 | 2020-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $228.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.69 | 2021-2023 | Trintellix |
| Eisai INC. | $161.16 | 2021-2022 | |
| Integra Lifesciences Corporation | $149.74 | 2022-2023 | Durasorb Monofilament Mesh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.17 | 2019-2021 | |
| Bausch Health US, LLC | $140.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.42 | 2020-2021 | |
| Ibsa Pharma INC. | $131.71 | 2020-2023 | Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.85 | 2020-2021 | |
| Braintree Laboratories, INC. | $107.24 | 2019-2022 | |
| Abbvie INC. | $74.20 | 2021-2023 | Vraylar |
| Exact Sciences Corporation | $72.81 | 2023 | Cologuard Collection Kit |
| Davol INC. | $68.52 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $57.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $47.80 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $43.26 | 2019-2021 | |
| Glaxosmithkline, LLC. | $40.34 | 2022-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $38.79 | 2022 | |
| Axsome Therapeutics, INC. | $38.51 | 2023 | Auvelity |
| Pacira Pharmaceuticals Incorporated | $35.34 | 2019 | |
| Depuy Synthes Sales INC. | $33.46 | 2022 | |
| Amgen INC. | $30.93 | 2019 | |
| Lilly USA, LLC | $26.89 | 2019-2022 | |
| Sanofi Pasteur INC. | $25.89 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $24.36 | 2020 | |
| Zimmer Biomet Holdings, INC. | $23.68 | 2024 | Ribfix Blu Advantage |
| Innocoll Pharmaceuticals Limited | $23.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.54 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $19.35 | 2019 | |
| Allergan, INC. | $16.70 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.09 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Toyama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.